Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The investigator, the subject, and the sponsor's project team will remain blind throughout
the study. Subjects will be randomly assigned to one of the three treatment groups at a ratio
of 1:1:1 to be given the drug once a day for 4 weeks.